Discusses the increase in the risk of school-aged children carrying excess body fat for
developing chronic disease. Concerns over the problem of childhood obesity; Calls for …

Prescriptions for second-generation antipsychotics (SGAs) have surpassed those for first-
generation agents in the treatment of schizophrenia and bipolar disorder. While SGAs have …

The lifespan of people with severe mental illness (SMI) is shorter compared to the general
population. This excess mortality is mainly due to physical illness. We report prevalence …

Introduction Antipsychotics (AP) induce weight gain. However, reviews and meta-analyses
generally are restricted to second generation antipsychotics (SGA) and do not stratify for …

AIM: We analysed the impact of tobacco smoking over several healthy lifestyle habits along
with the impact on 10-years cardiovascular event (CVE) risk in the CLAMORS schizophrenia …

Background: Weight gain is a side effect of therapy with many atypical antipsychotics and
may have important clinical repercussions with respect to long-term health and treatment …

AIM: To assess the prevalence of Coronary Heart Disease (CHD) and Metabolic Syndrome
(MS) in patients treated with antipsychotics. METHODS: Retrospective, cross-sectional …

Quetiapine (Seroquel®), a dibenzothiazepine derivative, is an atypical antipsychotic with
demonstrated efficacy in acute schizophrenia. In short-term, randomised, double-blind trials …

Background Nonadherence/discontinuation of antipsychotic (AP) medications represents an
important clinical issue in patients across psychiatric disorders, including schizophrenia …

Background: The main objective was to assess the efficacy of a weight management
program designed for outpatients taking olanzapine for schizophrenia or schizoaffective …